Insider Trading Alert - GMCR, ALKS And INUV Traded By Insiders

Yesterday, Sept. 2, 2015, 92 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $34.60 to $483,696,928,500.00.

Highlighted Stocks Traded by Insiders:

Keurig Green Mountain (GMCR) - FREE Research Report

Mardy Michael J, who is Director at Keurig Green Mountain, bought 1,000 shares at $55.25 on Sept. 2, 2015. Following this transaction, the Director owned 12,164 shares meaning that the stake was boosted by 8.96% with the 1,000-share transaction.

Kilsby Susan S, who is Director at Keurig Green Mountain, bought 5,000 shares at $56.76 on Sept. 2, 2015. Following this transaction, the Director owned 15,502 shares meaning that the stake was boosted by 47.61% with the 5,000-share transaction.

The shares most recently traded at $57.30, up $0.54, or 0.94% since the insider transaction. Historical insider transactions for Keurig Green Mountain go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 1,258
  • 12-Week # shares bought: 28,500
  • 12-Week # shares sold: 1,258
  • 24-Week # shares bought: 28,500
  • 24-Week # shares sold: 1,258

The average volume for Keurig Green Mountain has been 2.5 million shares per day over the past 30 days. Keurig Green Mountain has a market cap of $8.5 billion and is part of the consumer goods sector and food & beverage industry. Shares are down 57.28% year-to-date as of the close of trading on Wednesday.

Keurig Green Mountain, Inc. produces and sells specialty coffee, coffeemakers, teas, and other beverages in the United States and Canada. The stock currently has a dividend yield of 2.09%. The company has a P/E ratio of 15.4. Currently, there are 2 analysts who rate Keurig Green Mountain a buy, 1 analyst rates it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GMCR - FREE

TheStreet Quant Ratings rates Keurig Green Mountain as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and feeble growth in the company's earnings per share. Get the full Keurig Green Mountain Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alkermes (ALKS) - FREE Research Report

Breyer Robert A, who is Director at Alkermes, sold 2,000 shares at $61.43 on Sept. 2, 2015. Following this transaction, the Director owned 43,156 shares meaning that the stake was reduced by 4.43% with the 2,000-share transaction.

The shares most recently traded at $63.49, up $2.06, or 3.24% since the insider transaction. Historical insider transactions for Alkermes go as follows:

  • 4-Week # shares bought: 1,600
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 1,600
  • 12-Week # shares sold: 4,000
  • 24-Week # shares bought: 1,600
  • 24-Week # shares sold: 8,000

The average volume for Alkermes has been 970,400 shares per day over the past 30 days. Alkermes has a market cap of $8.9 billion and is part of the health care sector and drugs industry. Shares are up 7.77% year-to-date as of the close of trading on Wednesday.

Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. Currently, there are 5 analysts who rate Alkermes a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALKS - FREE

TheStreet Quant Ratings rates Alkermes as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Alkermes Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Inuvo (INUV) - FREE Research Report

Conner F William, who is Director at Inuvo, bought 17,633 shares at $2.50 on Sept. 2, 2015. Following this transaction, the Director owned 397,706 shares meaning that the stake was boosted by 4.64% with the 17,633-share transaction.

The shares most recently traded at $2.55, up $0.05, or 1.97% since the insider transaction. Historical insider transactions for Inuvo go as follows:

  • 4-Week # shares bought: 26,588
  • 12-Week # shares bought: 26,588
  • 24-Week # shares bought: 26,588

The average volume for Inuvo has been 257,400 shares per day over the past 30 days. Inuvo has a market cap of $60.7 million and is part of the services sector and media industry. Shares are up 89.23% year-to-date as of the close of trading on Wednesday.

Inuvo, Inc., together with its subsidiaries, operates as an Internet marketing and technology company that delivers advertisements through various networks of Websites and applications reaching desktop and mobile devices in the United States. The company has a P/E ratio of 27.8. Currently, there are 3 analysts who rate Inuvo a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on INUV - FREE

TheStreet Quant Ratings rates Inuvo as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Inuvo Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Dow Slumps Further as Wall Street Grapples With Growth Concerns

Dow Slumps Further as Wall Street Grapples With Growth Concerns

Sell Apple's Suppliers in Asia as Holidays Fail to Bring Cheer

Sell Apple's Suppliers in Asia as Holidays Fail to Bring Cheer

Jim Cramer on Johnson & Johnson, the Santa Claus Rally and the State of Gold

Jim Cramer on Johnson & Johnson, the Santa Claus Rally and the State of Gold

Jack in the Box Rises as Company Explores Sale

Jack in the Box Rises as Company Explores Sale

A Johnson & Johnson Equity Stake Is Out of the Question Right Now

A Johnson & Johnson Equity Stake Is Out of the Question Right Now